國立虎尾科技大學 |

Acute Myeloid Leukemia

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Acute Myeloid Leukemia / edited by Christoph Röllig, Gert J. Ossenkoppele.
其他作者:	Ossenkoppele, Gert J.
面頁冊數:	VIII, 358 p. 45 illus., 40 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Hematology. -
電子資源:	https://doi.org/10.1007/978-3-030-72676-8
ISBN:	9783030726768

Acute Myeloid Leukemia
Acute Myeloid Leukemia [electronic resource] /edited by Christoph Röllig, Gert J. Ossenkoppele. - 1st ed. 2021. - VIII, 358 p. 45 illus., 40 illus. in color.online resource. - Hematologic Malignancies,2197-9774. - Hematologic Malignancies,.

1. Epidemiology and Etiology -- 2. Diagnosis and Classification of AML: WHO 2016 -- 3. The Genomic Landscape and Clonal Evolution of AML -- 4. Clinical Manifestation and Diagnostic Workup -- 5. Prognostic Factors and Treatment Allocation -- 6. Treatment of Acute Promyelocytic Leukemia -- 7. Treatment of Newly Diagnosed AML in FitPatients -- 8. Treatment of Newly Diagnosed AML in Unfit Patients -- 9. Treatment of Relapsed and Refractory AML -- 10. Allogeneic Stem Cell Transplantation -- 11. Special Clinical Scenarios -- 12. Future Developments.

This book, written by a team of leading experts, provides a comprehensive overview of acute myeloid leukemia (AML), the most frequent acute leukemia in adults. The opening chapters present current knowledge of epidemiology, etiologic factors, and the pathogenesis and molecular development of AML. Detailed guidance is offered on laboratory and clinical diagnostic workup and disease classification, and the patient- and disease-related factors that determine prognosis and treatment allocation are identified. On the basis of these general considerations, initial treatments in patients considered fit for intensive treatment and in older and co-morbid patients are reviewed, and the available relapse treatment strategies, explained. For all clinical scenarios, the most recent data on the optimal use of newly approved agents in different AML subgroups are presented. Separate chapters address the treatment of acute promyelocytic leukemia, current practice of allogeneic stem cell transplantation, and special clinical situations. Finally, promising approaches in drug development, current standards and challenges in assessment of measurable residual disease, immune approaches, and ideas for innovative trial designs are considered.

ISBN: 9783030726768

Standard No.: 10.1007/978-3-030-72676-8doiSubjects--Topical Terms:

645254
Hematology.

LC Class. No.: RB45

Dewey Class. No.: 616.15

Acute Myeloid Leukemia
LDR:03163nam a22004095i 4500 001 1054326
003 DE-He213
005 20210818162431.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030726768 $9 978-3-030-72676-8
024 7 $a 10.1007/978-3-030-72676-8 $2 doi
035 $a 978-3-030-72676-8
050 4 $a RB45
072 7 $a MJF $2 bicssc
072 7 $a MED038000 $2 bisacsh
072 7 $a MJF $2 thema
082 0 4 $a 616.15 $2 23
245 1 0 $a Acute Myeloid Leukemia $h [electronic resource] / $c edited by Christoph Röllig, Gert J. Ossenkoppele.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a VIII, 358 p. 45 illus., 40 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Hematologic Malignancies, $x 2197-9774
505 0 $a 1. Epidemiology and Etiology -- 2. Diagnosis and Classification of AML: WHO 2016 -- 3. The Genomic Landscape and Clonal Evolution of AML -- 4. Clinical Manifestation and Diagnostic Workup -- 5. Prognostic Factors and Treatment Allocation -- 6. Treatment of Acute Promyelocytic Leukemia -- 7. Treatment of Newly Diagnosed AML in FitPatients -- 8. Treatment of Newly Diagnosed AML in Unfit Patients -- 9. Treatment of Relapsed and Refractory AML -- 10. Allogeneic Stem Cell Transplantation -- 11. Special Clinical Scenarios -- 12. Future Developments.
520 $a This book, written by a team of leading experts, provides a comprehensive overview of acute myeloid leukemia (AML), the most frequent acute leukemia in adults. The opening chapters present current knowledge of epidemiology, etiologic factors, and the pathogenesis and molecular development of AML. Detailed guidance is offered on laboratory and clinical diagnostic workup and disease classification, and the patient- and disease-related factors that determine prognosis and treatment allocation are identified. On the basis of these general considerations, initial treatments in patients considered fit for intensive treatment and in older and co-morbid patients are reviewed, and the available relapse treatment strategies, explained. For all clinical scenarios, the most recent data on the optimal use of newly approved agents in different AML subgroups are presented. Separate chapters address the treatment of acute promyelocytic leukemia, current practice of allogeneic stem cell transplantation, and special clinical situations. Finally, promising approaches in drug development, current standards and challenges in assessment of measurable residual disease, immune approaches, and ideas for innovative trial designs are considered.
650 0 $a Hematology. $3 645254
700 1 $a Ossenkoppele, Gert J. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1359380
700 1 $a Röllig, Christoph. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1359379
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030726751
776 0 8 $i Printed edition: $z 9783030726775
776 0 8 $i Printed edition: $z 9783030726782
830 0 $a Hematologic Malignancies, $x 2197-9766 $3 1253495
856 4 0 $u https://doi.org/10.1007/978-3-030-72676-8
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)